- Haliey Welch releases first statement after going MIA following ‘Hawk Tuah’ crypto crash
- Why Is Bitcoin Surging? This Expert Forecasts $180K Bitcoin Price in 2025
- Impact on Bitcoin and Taxation in France
- Eyal Avramovich Discusses Innovation, Cryptocurrency, and His Vision for the Future
- Ventura County man accused in $22M cryptocurrency fraud case
Quantum BioPharma (NASDAQ:QNTM) has announced a strategic investment of USD $1,000,000 in Bitcoin (BTC) and other cryptocurrencies following Board approval. The company will also accept cryptocurrency for future financings and transactions, storing all digital assets with a compliant custodian.
Bạn đang xem: Quantum BioPharma Makes Bold $1M Bitcoin Investment, Embraces Crypto for Future Transactions
CEO Zeeshan Saeed cited Bitcoin’s increased legal and market legitimacy, including the emergence of BTC-based ETFs and anticipated pro-crypto policies, as key factors in this decision. The company maintains flexibility to adjust its cryptocurrency holdings based on market conditions, viewing this investment as an opportunity to grow non-operational capital while aligning with emerging financial trends.
Quantum BioPharma (NASDAQ:QNTM) ha annunciato un investimento strategico di USD $1,000,000 in Bitcoin (BTC) e altre criptovalute a seguito dell’approvazione del Consiglio. L’azienda accetterà anche criptovalute per futuri finanziamenti e transazioni, conservando tutti gli asset digitali presso un custode conforme.
Il CEO Zeeshan Saeed ha citato l’aumento della legittimità legale e di mercato del Bitcoin, inclusa l’emergere di ETF basati su BTC e politiche pro-crypto previste, come fattori chiave in questa decisione. L’azienda mantiene la flessibilità di adeguare le proprie partecipazioni in criptovalute in base alle condizioni di mercato, vedendo questo investimento come un’opportunità per far crescere il capitale non operativo mentre si allinea con le tendenze finanziarie emergenti.
Quantum BioPharma (NASDAQ:QNTM) ha anunciado una inversión estratégica de USD $1,000,000 en Bitcoin (BTC) y otras criptomonedas tras la aprobación de la Junta. La empresa también aceptará criptomonedas para futuros financiamientos y transacciones, almacenando todos los activos digitales con un custodio conforme.
El CEO Zeeshan Saeed citó el aumento de la legitimidad legal y de mercado de Bitcoin, incluida la aparición de ETFs basados en BTC y políticas anticipadas pro-crypto, como factores clave en esta decisión. La empresa mantiene la flexibilidad de ajustar sus tenencias de criptomonedas en función de las condiciones del mercado, viendo esta inversión como una oportunidad para hacer crecer el capital no operativo mientras se alinea con las tendencias financieras emergentes.
Quantum BioPharma (NASDAQ:QNTM)는 이사회 승인을 받은 후 USD $1,000,000을 비트코인(BTC) 및 기타 암호화폐에 전략적으로 투자한다고 발표했습니다. 이 회사는 또한 향후 자금 조달 및 거래를 위해 암호화폐를 수용하며, 모든 디지털 자산을 준수하는 수탁자에게 보관할 것입니다.
CEO 제시한 사이드(Zeeshan Saeed)는 비트코인의 법적 및 시장 합법성 증가, BTC 기반 ETF의 출현 및 예상되는 친암호화 정책이 이 결정의 핵심 요소라고 언급했습니다. 회사는 시장 상황에 따라 암호화폐 보유를 조정할 수 있는 유연성을 유지하며, 이 투자를 비운영 자본을 성장시킬 수 있는 기회로 보고 있으며, 신흥 금융 트렌드와 일치하고 있습니다.
Quantum BioPharma (NASDAQ:QNTM) a annoncé un investissement stratégique de USD $1,000,000 dans le Bitcoin (BTC) et d’autres cryptomonnaies suite à l’approbation du Conseil. L’entreprise acceptera également les cryptomonnaies pour de futurs financements et transactions, en stockant tous les actifs numériques auprès d’un dépositaire conforme.
Le PDG Zeeshan Saeed a cité l’augmentation de la légitimité légale et commerciale du Bitcoin, y compris l’émergence d’ETF basés sur le BTC et les politiques pro-crypto anticipées, comme des facteurs clés dans cette décision. L’entreprise conserve la flexibilité d’ajuster ses avoirs en cryptomonnaie en fonction des conditions du marché, considérant cet investissement comme une opportunité de faire croître le capital non opérationnel tout en s’alignant sur les tendances financières émergentes.
Xem thêm : Remote enables USDC crypto payouts for contractors
Quantum BioPharma (NASDAQ:QNTM) hat eine strategische Investition in Höhe von USD $1,000,000 in Bitcoin (BTC) und andere Kryptowährungen nach der Genehmigung durch den Vorstand angekündigt. Das Unternehmen wird auch Kryptowährungen für künftige Finanzierungen und Transaktionen akzeptieren und alle digitalen Vermögenswerte bei einem konformen Treuhänder lagern.
CEO Zeeshan Saeed nannte die gestiegene rechtliche und marktliche Legitimität von Bitcoin, einschließlich des Auftretens von BTC-basierten ETFs und der erwarteten pro-Krypto-Politik, als Schlüsselfaktoren für diese Entscheidung. Das Unternehmen behält sich die Flexibilität vor, seine Kryptowährungsbestände basierend auf den Marktbedingungen anzupassen, und sieht diese Investition als eine Gelegenheit, das nicht betriebliche Kapital zu steigern und sich gleichzeitig an den aufkommenden finanziellen Trends zu orientieren.
Positive
- Strategic diversification of treasury with $1,000,000 investment in cryptocurrencies
- New capability to accept cryptocurrency for future financing and transactions
- Secure storage through compliant custodian ensuring regulatory compliance
Negative
- Exposure to cryptocurrency market volatility and risks
- Investment of operational capital in highly speculative assets
Insights
The company’s cryptocurrency strategy introduces significant risk factors that warrant careful scrutiny. While they’ve implemented proper custody solutions and regulatory compliance measures, the inherent volatility of crypto assets could impact their financial stability. For a biotech company with a relatively small market cap of
This strategic pivot raises notable governance considerations. While board approval provides proper oversight, the decision to invest in cryptocurrencies represents an unusual departure from traditional biotech treasury management practices. The company’s market cap suggests they’re a smaller player, making this allocation potentially more impactful on their overall financial health. Their emphasis on regulatory compliance and use of qualified custodians shows awareness of institutional requirements, but accepting future financing in cryptocurrency could create additional governance challenges around valuation, disclosure and investor rights. The timing of this announcement, coupled with speculation about future political impacts, may raise questions about the board’s long-term strategic planning and risk appetite.
TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) (“Quantum BioPharma” or the “Company“), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased USD
This move reflects the company’s belief in the potential of Bitcoin (BTC) and other currencies to provide a return on investment for shareholders. The company is now set up to receive financing in cryptocurrencies as well as executing other types of transactions in cryptocurrencies.
The company is holding all its cryptocurrency with a fully compliant custodian. The company emphasizes that all transactions are and will be fully compliant with all relevant financial and audit regulations, ensuring a secure and legal process.
The Company will continue to monitor market conditions and may increase or decrease its holdings of Bitcoin (BTC) or other cryptocurrencies as it deems appropriate.
“We are exploring innovative ways to grow our capital not being used in operations,” said Zeeshan Saeed, CEO of Quantum. “Bitcoin’s recent advancements in both legal and market legitimacy make it a compelling addition. With multiple global asset managers now offering BTC based exchange-traded funds, and renewed optimism following pro-crypto policy expectations under President-elect Donald Trump’s new administration, we believe Bitcoin (BTC), and other cryptocurrencies presents an opportunity to align with emerging financial trends.”
About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid“), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition“), led by industry veterans. Quantum BioPharma retains ownership of
Xem thêm : What Happens to Confiscated Crypto? US Asset Forfeiture Laws
Forward-Looking Information
Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such.
Forward-looking information in this press release are based on certain assumptions and expected future events.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: [email protected]
Telephone: (416) 854-8884
Investor Relations
Email: [email protected], [email protected]
Website: www.quantumbiopharma.com
SOURCE: Quantum BioPharma Ltd.
View the original press release on accesswire.com
FAQ
How much did Quantum BioPharma (QNTM) invest in Bitcoin and cryptocurrencies?
Quantum BioPharma invested USD $1,000,000 in Bitcoin (BTC) and other cryptocurrencies as announced on December 20, 2024.
Will Quantum BioPharma (QNTM) accept cryptocurrency for future transactions?
Yes, Quantum BioPharma will accept cryptocurrencies for future financing and other transactions, as announced in their strategic initiative.
How does Quantum BioPharma (QNTM) store its cryptocurrency holdings?
Quantum BioPharma stores all its cryptocurrency holdings with a fully compliant custodian to ensure security and regulatory compliance.
What influenced QNTM’s decision to invest in cryptocurrencies?
The decision was influenced by Bitcoin’s increased legal and market legitimacy, the emergence of BTC-based ETFs, and anticipated pro-crypto policies under the upcoming administration.
Can Quantum BioPharma (QNTM) adjust its cryptocurrency holdings in the future?
Yes, the company stated it will monitor market conditions and may increase or decrease its holdings of Bitcoin or other cryptocurrencies as deemed appropriate.
Nguồn: https://gapinsurance.click
Danh mục: News
